Loading data for VCEL — first visit, this takes a few seconds.
Vericel Corporation (VCEL)
NasdaqGM: VCEL
· Real-Time Price · USD
42.11
-1.46 (-3.35%)
At close: Aug 20, 2026, 8:00 PM
42.11
+0.00%
After-hours: 7:30 PM
Vericel Corporation (VCEL) Stock Price, Analysis & Data
-3.35% (1D)
No data available
| Bid | 39.62 |
| Market Cap | 2.16B |
| Revenue (ttm) | 306.3M |
| Net Income (ttm) | 24.22M |
| Beta | 1.07 |
| EPS (ttm) | 0.48 |
| PE Ratio (ttm) | 87.73 |
| Forward PE | 49.78 |
| P/B (ttm) | 5.82 |
| P/S (ttm) | 7.04 |
| Earnings Date | Nov 5, 2026 |
| Ask | 52.78 |
| Volume | 567,684 |
| Avg. Volume (20D) | 579,677 |
| Open | 42.83 |
| Previous Close | 43.57 |
| Day's Range | 41.68 - 43.48 |
| 52-Week Range | 28.95 - 49.32 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 1997
Employees 398
Stock Exchange NasdaqGM
Ticker Symbol VCEL
Website https://www.vcel.com
Financial Performance
In 2025, Vericel's revenue was 276.26M, an increase of 16.45% compared to the previous year's 237.22M. Earnings were 16.52M, an increase of 59.41%.
Financial StatementsEarnings Surprise
Vericel has released their quarterly earnings on Jul 30, 2026:
Vericel Corporation is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2